

Daftar Pustaka

A. Kinoshita, H. Onoda, N. Fushiya, K. Koike, H. Nishino, and H. Tajiri, "Staging systems for hepatocellular carcinoma: Current status and future perspectives," *World J. Hepatol.*, vol. 7, no. 3, pp. 406–424, 2015, doi: 10.4254/wjh.v7.i3.406.

American College of Radiology. Liver imaging reporting and data system version 2018. Available at: <http://www.acr.org/Home/ClinicalResources/ReportingandDataSystem/LIRADS/CT/MRILIRADsv2018>. Accessed April 22, 2023.

Boutros C, Somasundar P, Garrean S, Saied A, Espat NJ. Microwave coagulation therapy for hepatic tumors: review of the literature and critical analysis. *Surg Oncol* 2010;19:e22-e32.

Brody RI, Theise ND. An inflammatory proposal for hepatocarcinogenesis. *Hepatology* 2012;56(1):382–384.

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2017;389:56-66.

Brunicaudi FC, Andersen DK, Billiar TR, et al. Schwartz's principles of surgery. 9th edition. New York: McGraw-Hill Publishing; 2010. p. 31–5.

C. Aubéa,b,* , A. Bouvier a , J. Lebigot a , et al. Radiological treatment of HCC: Interventional radiology at the heart of management. Elsevier Masson: *Diagnostic and Interventional Imaging* (2015) 96, 625—636.

Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxì A and Cottone M: Transarterial chemoembolization for resectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. *Radiology* 224: 47-54, 2002.



Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. *Hepatology* 2009;49:453-459.

Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012; *Ultrasound Med Biol* 2013; 39 (2): 187-210.

David P. Dorn, Mary K. Bryant, Jessica Zarzou et al. Chemoembolization outcomes for hepatocellular carcinoma in cirrhotic patients with compromised liver function. Derek A. DuBay, Liver Transplant and Hepatobiliary Surgery, University of Alabama at Birmingham. DOI:10.1111/hpb.12194.

Diwakar S, Akshatha N. Srinivas and Divya P. Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. *Frontiers in Oncology*, published: 30 November 2020, doi: 10.3389/fonc.2020.601710.

European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. *Journal of Hepatology* 2012 vol. 56 j 908–943

Fornier A, Llovet JM, Bruix J. Hepatocellular carcinoma. *Lancet* 2012;379:1245–55.

Frenette C, Gish RG. Hepatocellular carcinoma: molecular and genomic guideline for the clinician. *Clin Liver Dis* 2011;15(2): 307–21.

Globocan 2018, “Liver Cancer Global WHO Report,” *Iarc*, vol. 876, pp. 2018–2019, 2018, [Online]. Available: <http://gco.iarc.fr/today>.

Groupe d'étude et de traitement du carcinome hépatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. *The new england journal of medicine*. Vol. 332



).

H.J. Yoon, J.H. Kim, K.A. Kim; Transcatheter arterial chemo-lipiodol infusion for unresectable hepatocellular carcinoma in 96 high-risk patients. The Royal College of Radiologists. Elsevier. Doi:10.1016/j.crad.2010.01.018.

Hanna RF, Aguirre DA, Kased N, Emery SC, Peterson MR, Sirlin CB. Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features. Radiographics 2008; 28: 747–769.

I. M. Loho, L. Siregar, A. S. Waspodo, and I. Hasan, “Current Practice of Hepatocellular Carcinoma Surveillance,” Acta Med. Indones., vol. 50, no. 4, pp. 353–360, 2018.

Ichikawa T, Machida N, Sasaki H, et al. Early prediction of the outcome using tumor markers and mrecist in unresectable hepatocellular carcinoma patients who underwent transarterial chemoembolization. Oncology 2016;91:317–30.

J. A. Marrero et al., “Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases,” Hepatology, vol. 68, no. 2, pp. 723–750, 2018, doi: 10.1002/hep.29913.

Javaria Isram, Rashk E Hinna, Muhammad Usman Munir et al. Predictors of Hepatic Decompensation after TACE for Hepatocellular Carcinoma Secondary to Chronic Hepatitis C. Eurasian Journal of Medicine and Oncology. DOI: 10.14744/ejmo.2023.41870.

Jean-Marc Idée, Boris Guiu b. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: A review. Critical Reviews in Oncology/Hematology 88 (2013) 530–549. <http://dx.doi.org/10.1016/j.critrevonc.2013.07.00>

Khalili K, Kim TK, Jang HJ, Yazdi LK, Guindi M, Sherman M. Indeterminate 1-2-cm nodules found on hepatocellular carcinoma surveillance: biopsy for all, some, or none? Hepatology 2011;54(6):2048–2054.



wler KJ, Lewis S, et al. Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. Abdominal Imaging (NY) 2018;43(1):218–30.

Kim SH, Lee J, et al. Gadoteric acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. *AJR Am J Roentgenol* 2009; 192(6): 1675-81.

Kudo M, Han G, Finn RS, Poon RT, Blanc JF, Yan L, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. *Hepatology* 2014;60:1697-1707.

[Llovet JM](#), [Ducreux M](#), [Lencioni R](#), et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *Eur J Cancer* 2012; 56(4): 908-43.

Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J and Bruix J; Barcelona Liver Cancer Group: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet* 359: 1734-1739, 2002.

Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST and Wong J: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. *Hepatology* 35: 1164-1171, 2002.

Luca A, Caruso S, Milazzo M, et al. Multidetector-row computed tomography (MDCT) for the diagnosis of hepatocellular carcinoma in cirrhotic candidates for liver transplantation: prevalence of radiological vascular patterns and histological correlation with liver explants. *Eur Radiol* 2010; 20(4): 898–907.

Malek NP, Schmidt S, Huber P, Manns MP, Greten TF. The diagnosis and treatment of hepatocellular carcinoma. *Gastroenterology* 2014; 111(7): 101-6.

MingDe Lin, PhD, Olivier Pellerin. Quantitative and Volumetric European Association for the Study of the Liver and Response Evaluation Criteria in



Tumors Measurements: Feasibility of a Semiautomated Software to Assess Tumor Response after Transcatheter Arterial Chemoembolization. *J Vasc Interv Radiol* 2012; 23:1629–1637

[dx.doi.org/10.1016/j.jvir.2012.08.028](https://doi.org/10.1016/j.jvir.2012.08.028)

N. Nishikawa, Y. Osaki, R. Kita, comparison of transcatheter arterial chemoembolization and transcatheter arterial chemotherapy infusion for patients with intermediate-stage hepatocellular carcinoma, *Oncology reports* 31: 65-72, 2014, P 65-71, DOI: 10.3892/or.2013.2845.

Nathan H, Pawlik TM. Staging of hepatocellular carcinoma. In: Masters KM, Vauthey J-N, editors. *Hepatocellular Carcinoma*. 2011. Berlin, Germany: Springer:69–80.

National cancer institute at national institutes of health, U.S Department of health and human services, <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/overall-survival>, Diakses tanggal : 26/01/2023

Oliver JH, Baron RL: State of the art, helical biphasic contrast enhanced CT of the liver: Technique, indications, interpretation, and pitfalls. *Radiology* 1996; 201:1-14.

Park YN. Update on precursor and early lesions of hepatocellular carcinomas. *Arch Pathol Lab Med* 2011;135(6):704–715.

R.Lencioni, T. Baere. Lipiodol Transarterial Chemoembolization for Hepatocellular Carcinoma: A Systematic Review of Efficacy and Safety Data. *American Association for the Study of Liver Diseases*. DOI 10.1002/hep.28453.

Rao PN. Nodule in Liver: Investigations, Differential Diagnosis and Follow-up. *J Clin Exp Hepatol* 2014; 4(3): 57-62.

S Anurag, M Prasanth, A. V. Kulkarn. Interventional Radiological Treatment of Hepatocellular Carcinoma: An Update. *Indian J Surg* (January–February 2012) 74(1):91–99

Serste T, Barrau V, Ozenne V, et al. Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. *Journal of Hepatology* 2012;55(3): 800–6.



, Harris J. Claude Couinaud: a passion for the liver. *Arch Surg* 2002; 137(1):1305–10.

Takayasu K, Arai S, Ikai I, Kudo M, Matsuyama Y, Kojiro M and Makuuchi M; Liver Cancer Study Group of Japan: Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. *AJR Am J Roentgenol* 194: 830-837, 2010.

Theise ND, Curado MP, Franceschi S, et al. Hepatocellular carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. *WHO Classification of Tumours of the Digestive System*. 4th ed. Lyon, France: IARC, 2010; 205–216.

Trevisani F, Cantarini MC, Wands JR, Bernardi M. Recent advances in the natural history of hepatocellular carcinoma. *Carcinogenesis* 2008;29(7):1299–1305.

Van Malenstein H, van Pelt J, Verslype C. Molecular classification of hepatocellular carcinoma anno 2011. *Eur J Cancer* 2011; 47(12):1789–1797.

Victor L. Scott II, Kerri M. Wahl, Kyle Soltys, Kumar G. Belani, David S. Beebe, Peter J. Davis. CP score and tumor size, BCLC uses the Eastern Cooperative Oncology Group (ECOG) scale to evaluate performance status (PS). *Smith's Anesthesia for Infants and Children (Eighth Edition)*, 2011. doi.10.1016/B978-0-323-06612-9.00028-6.

W. Desen and W. Japaries, *Buku Ajar Onkologi Klinis Edisi 2*. Jakarta: FKUI, 2013.

Wong RJ, Ahmed A, Gish RG. Elevated alpha-fetoprotein differential diagnosis-hepatocellular carcinoma and other disorders. *Clin Liver Dis* 2015; 19(2): 309-23.

World Health Organization, "Indonesia Source GLOBOCAN 2018," *Int. Agency Res. Cancer*, vol. 256, pp. 1–2, 2019, [Online]. Available: <http://gco.iarc.fr/>.

Wolff J. Physiology and pharmacology of iodized oil in goiter prophylaxis. *Medicine* 2001;80:20–36.



R, Zheng W, Hu H. Comprehensive Analysis of Factors Affecting al Response and Short-Term Survival to Drug-Eluting Bead

Transarterial Chemoembolization for Treatment in Patients with Liver Cancer. *Technology in Cancer Research and Treatment* 2018;17:1-15.

Yau T, Yao TJ, Chan P, et al. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. *Oncologist* 2011;16:1270–9. [11] Nakazawa T, Hidaka H, Takada J, et al. Early increase in alphafetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. *Eur J Gastroenterol Hepatol* 2013;25:683–9.

